Overview

TORI 104 Pre-Surgical Dasatinib

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will examine the anti-tumor activity, safety and tolerability of dasatinib in adjuvant breast cancer patients in a pre-surgical setting.
Phase:
Phase 2
Details
Lead Sponsor:
AHS Cancer Control Alberta
Treatments:
Dasatinib